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ear Editor,
 previous in vitro investigation found that a sinergistic effect
ight occur, when using itraconazole (ITRA) and ritonavir
RTV) against Histoplasma capsulatum,1 where an interesting
echanism of action was proposed. However, relevant phar-
acokinetic (PK) issues were under explored. Herein, this
etter attempts to deepen a clinical PK discussion not per-
ormed by Brilhante and colleagues.1
Firstly, the in vitro model1 did not account for drug penetra-
ion in macrophages, given that Histoplasma spp. are found as
ntracellular microorganisms after innate immunity recogni-
ion and phagocytation.2 Secondly, one should recognize the
otential CYP3A4 competitive inhibition when using RTV and
n azolic agent. By combining them, we  expect an elevated
lasma concentration of the azolic agent,3 as RTV has higher
fﬁnity to the aforementioned phase 1 enzyme, but not the
pposite.1 The association of both drugs is a possible scenario4
hen treating multiple drug resistant HIV infected patients.
hether non-CYP3A4 substrates are unavailable, clinicians
hould attempt to monitoring hepatic enzymes and random
TRA steady state serum concentrations (>1 g/mL) after 7–15
ays.3
Finally, the previous report1 discussed that using both
rugs might be clinically possible by “reducing itraconazole
ose”. For several reasons,5 there is no evidence on lowering
TRA doses: (a) it has an erratic gastrointestinal absorption
nd food composition and gastric pH might inﬂuence drug’s
ioavailability (cyclodextrin-containing formulations are pre-
erred); (b) ITRA has non-linear PK, thus, dose reductions
ay lead to unpredictable serum levels (zero order kinetics
s dependent on enzyme saturation).onﬂicts  of  interest
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